Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.44 USD | +0.21% | -9.20% | +30.21% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.21% | 2.09B | |
+75.69% | 12.57B | |
+15.86% | 7.21B | |
-30.02% | 6.82B | |
+12.09% | 5.35B | |
+10.93% | 3.99B | |
-25.26% | 3.77B | |
-30.02% | 2.64B | |
-1.24% | 2.04B | |
+3.19% | 1.86B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Transcript : NovoCure Limited Presents at JP Morgan 37th Annual Healthcare conference, Jan-09-2019 02